Ascletis announced October 28 that its experimental once-daily tablet ASC30 reduced a measure of blood sugar compared with placebo in a U.S. Phase II diabetes trial.
The company reported placebo-adjusted HbA1c reductions of 1.7, 1.6 and 1.7 percentage points at 12 weeks for the 40-, 60- and 80-milligram groups, respectively. Participants' average starting HbA1c was 8.3%.
The randomized, double-blind study enrolled 100 people with type 2 diabetes. Its primary endpoint measured HbA1c at 12 weeks, while weight change at 13 weeks was a secondary endpoint.
Ascletis said there were no discontinuations caused by gastrointestinal adverse events and one discontinuation attributed to hiccups. The company reported no drug-related serious adverse events during the study.
These are the developer's topline findings from a relatively small, short trial. They do not establish long-term safety or regulatory approval. ASC30 remains investigational, and the company's separate Phase III obesity program addresses a different development program.
Sources Ascletis Pharma results announcement, distributed by PR Newswire, October 28, 2026.